Clearly, further research and dedicated experiments are required to fully explore and validate the potential of FFAR4 agonists in regulating the phenotype of macrophages toward an anti-inflammatory M2 activation state as a potential novel pharmacotherapy of atherosclerosis. Here, FFAR4 is linked to atherosclerosis.